SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Garth Richmond who wrote (1027)10/5/2000 8:07:55 AM
From: BostonView  Read Replies (1) of 1321
 
Matthew Geller, analyst at CIBC World Markets, said his opinion on QLT hasn't changed. "The stock has been affected by analysts who didn't listen to the company's guidance in the first place," he said.

This is pretty incriminating, if true. IMO, operating in a vacuum and with very limited data (polling a mere 40 docs?) is a very dangerous m.o., especially in this industry. It's hard to fathom that when presented with their own findings, Url wouldn't have contacted QLT directly and/or polled a larger sample of retinal docs to determine if they had simply encountered a statistical anomaly.

Time will tell.

BV
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News